{"id":48454,"date":"2022-09-15T19:02:18","date_gmt":"2022-09-15T17:02:18","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\/"},"modified":"2022-09-15T19:02:18","modified_gmt":"2022-09-15T17:02:18","slug":"revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\/","title":{"rendered":"RevBio Receives Approval from the U.K.\u2019s Regulatory Authority to Initiate a Clinical Trial for an Optimized Formulation of its Dental Bone Adhesive Biomaterial"},"content":{"rendered":"<div>\n<p>\n<i>RevBio Receives Approval to Start a Clinical Trial in the United Kingdom to Study a Modified Formulation of its Bone Adhesive Biomaterial for Implant Dentistry<\/i>\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220915005733\/en\/1573257\/5\/REVBIO_TETRANITE_GRAPH.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220915005733\/en\/1573257\/21\/REVBIO_TETRANITE_GRAPH.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20220915005733\/en\/1572659\/5\/RevBioHighRes_copy.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220915005733\/en\/1572659\/21\/RevBioHighRes_copy.jpg\"><\/a><\/p>\n<p>LOWELL, Mass.&#8211;(BUSINESS WIRE)&#8211;RevBio, Inc., announced that it has received approval from the Medicines and Healthcare products Regulatory Agency in the United Kingdom to start a 15-patient clinical trial to examine the safety and efficacy of immediately stabilized dental implants following tooth extractions using an optimized formulation of Tetranite\u00ae, the company\u2019s bone adhesive biomaterial.\n<\/p>\n<p>\nDr. Michael R. Norton, BDS, FDS, RCS(Ed), a London-based oral surgeon, noted lecturer, and former President of the Academy of Osseointegration, will serve as the chief investigator for this clinical trial. \u201cI am thrilled to be involved in this clinical trial which builds on the first one I completed earlier this year,\u201d said Dr. Norton. \u201cSince initiating the prior MHRA-approved study in the United Kingdom, RevBio has significantly improved the osteopromotive potential of its biomaterial.\u201d\n<\/p>\n<p>\nRevBio has optimized its bone adhesive biomaterial primarily by adjusting the pH of the material as it undergoes its self-setting reaction. In addition, the company has also increased the porosity of the material. Benchtop and animal testing has shown that these changes have improved the material\u2019s biocompatibility with the gingival tissues that surround tooth extraction sites. These formulation changes have also increased the substitution rate of new bone formation without sacrificing the biomaterial\u2019s ability to adhere to bone. In fact, this formulation is more adhesive than the company\u2019s prior dental formulation.\n<\/p>\n<p>\nSimilar to Dr. Norton\u2019s prior study, this new clinical trial will focus specifically on anterior teeth located in the aesthetic or \u201csmile\u201d zone where the loss of a tooth is highly visible. Patients will receive temporary crowns at the time their implants are placed which will obviate a costly, complex, and lengthy bone grafting process for many patients, greatly accelerating the overall treatment timeframe.\n<\/p>\n<p>\n\u201cWe are excited to partner again with Dr. Norton who is a thought leader in advancing clinical practice in the field of implant dentistry,\u201d said Alan Pollack, RevBio\u2019s Senior Director of Dental Clinical Operations. \u201cThe development of this new formulation has really advanced the company\u2019s ability to tune the biomaterial\u2019s performance to address anatomically-specific requirements.\u201d\n<\/p>\n<p>\n<b>About RevBio, Inc.<\/b>\n<\/p>\n<p>\nRevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial called Tetranite\u00ae. The company is initially developing this technology for use in the dental, cranial, and broader orthopaedic markets as well as applications in the animal health market. RevBio&#8217;s Tetranite technology is not yet approved for commercial use.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nMichael Tiedemann<br \/>\n<br \/>6177630923<br \/>\n<br \/><a target=\"_blank\" href=\"ma&#105;&#108;&#116;&#111;&#x3a;&#x6d;&#x74;&#x69;&#x65;de&#109;&#97;&#110;&#110;&#x40;&#x72;&#x65;&#x76;&#x62;io&#46;&#99;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x6d;&#x74;&#105;e&#x64;&#x65;&#109;an&#x6e;&#x40;&#114;e&#x76;&#x62;&#105;&#111;&#46;&#x63;&#x6f;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>RevBio Receives Approval to Start a Clinical Trial in the United Kingdom to Study a Modified Formulation of its Bone Adhesive Biomaterial for Implant Dentistry LOWELL, Mass.&#8211;(BUSINESS WIRE)&#8211;RevBio, Inc., announced that it has received approval from the Medicines and Healthcare products Regulatory Agency in the United Kingdom to start a 15-patient clinical trial to examine &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48454","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>RevBio Receives Approval from the U.K.\u2019s Regulatory Authority to Initiate a Clinical Trial for an Optimized Formulation of its Dental Bone Adhesive Biomaterial - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RevBio Receives Approval from the U.K.\u2019s Regulatory Authority to Initiate a Clinical Trial for an Optimized Formulation of its Dental Bone Adhesive Biomaterial - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"RevBio Receives Approval to Start a Clinical Trial in the United Kingdom to Study a Modified Formulation of its Bone Adhesive Biomaterial for Implant Dentistry LOWELL, Mass.&#8211;(BUSINESS WIRE)&#8211;RevBio, Inc., announced that it has received approval from the Medicines and Healthcare products Regulatory Agency in the United Kingdom to start a 15-patient clinical trial to examine ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-15T17:02:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220915005733\/en\/1573257\/21\/REVBIO_TETRANITE_GRAPH.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"RevBio Receives Approval from the U.K.\u2019s Regulatory Authority to Initiate a Clinical Trial for an Optimized Formulation of its Dental Bone Adhesive Biomaterial\",\"datePublished\":\"2022-09-15T17:02:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\\\/\"},\"wordCount\":474,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220915005733\\\/en\\\/1573257\\\/21\\\/REVBIO_TETRANITE_GRAPH.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\\\/\",\"name\":\"RevBio Receives Approval from the U.K.\u2019s Regulatory Authority to Initiate a Clinical Trial for an Optimized Formulation of its Dental Bone Adhesive Biomaterial - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220915005733\\\/en\\\/1573257\\\/21\\\/REVBIO_TETRANITE_GRAPH.jpg\",\"datePublished\":\"2022-09-15T17:02:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220915005733\\\/en\\\/1573257\\\/21\\\/REVBIO_TETRANITE_GRAPH.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220915005733\\\/en\\\/1573257\\\/21\\\/REVBIO_TETRANITE_GRAPH.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RevBio Receives Approval from the U.K.\u2019s Regulatory Authority to Initiate a Clinical Trial for an Optimized Formulation of its Dental Bone Adhesive Biomaterial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RevBio Receives Approval from the U.K.\u2019s Regulatory Authority to Initiate a Clinical Trial for an Optimized Formulation of its Dental Bone Adhesive Biomaterial - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\/","og_locale":"en_US","og_type":"article","og_title":"RevBio Receives Approval from the U.K.\u2019s Regulatory Authority to Initiate a Clinical Trial for an Optimized Formulation of its Dental Bone Adhesive Biomaterial - Pharma Trend","og_description":"RevBio Receives Approval to Start a Clinical Trial in the United Kingdom to Study a Modified Formulation of its Bone Adhesive Biomaterial for Implant Dentistry LOWELL, Mass.&#8211;(BUSINESS WIRE)&#8211;RevBio, Inc., announced that it has received approval from the Medicines and Healthcare products Regulatory Agency in the United Kingdom to start a 15-patient clinical trial to examine ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-15T17:02:18+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220915005733\/en\/1573257\/21\/REVBIO_TETRANITE_GRAPH.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"RevBio Receives Approval from the U.K.\u2019s Regulatory Authority to Initiate a Clinical Trial for an Optimized Formulation of its Dental Bone Adhesive Biomaterial","datePublished":"2022-09-15T17:02:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\/"},"wordCount":474,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220915005733\/en\/1573257\/21\/REVBIO_TETRANITE_GRAPH.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\/","url":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\/","name":"RevBio Receives Approval from the U.K.\u2019s Regulatory Authority to Initiate a Clinical Trial for an Optimized Formulation of its Dental Bone Adhesive Biomaterial - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220915005733\/en\/1573257\/21\/REVBIO_TETRANITE_GRAPH.jpg","datePublished":"2022-09-15T17:02:18+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220915005733\/en\/1573257\/21\/REVBIO_TETRANITE_GRAPH.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220915005733\/en\/1573257\/21\/REVBIO_TETRANITE_GRAPH.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-from-the-u-k-s-regulatory-authority-to-initiate-a-clinical-trial-for-an-optimized-formulation-of-its-dental-bone-adhesive-biomaterial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"RevBio Receives Approval from the U.K.\u2019s Regulatory Authority to Initiate a Clinical Trial for an Optimized Formulation of its Dental Bone Adhesive Biomaterial"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48454","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48454"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48454\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48454"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48454"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48454"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}